KEELE, England, July 27 /PRNewswire/ -- A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, ( http://www.biocomposites.com), as an effective bone replacement material demonstrating superior bone regenerative properties due to its unique negative zeta potential control (ZPC(TM)).
The research carried out by the hospital and departments of the university of Aachen and the Universities of Munich and Regensburg, Germany, analysed the osteogenic potential of Fortoss Vital for maxillary sinus floor augmentation on a 61 year old female. The samples taken from the graft site at 6 months, showed the negative surface charge of Fortoss Vital had accelerated the bone formation cascade and rapidly produced mature lamellar bone formation with marrow cavities. The bone density at the graft site was shown to be denser than the original bone matrix of the posterior maxillary region. Evidence also confirmed the complete resorption of Fortoss Vital.
Fortoss Vital is a unique, bi-phasic calcium composite bone graft material having a negative surface charge which attracts the key proteins and cells for rapid osteogenesis and bone repair. Fortoss Vital is fully resorbed by osteoclastic processes and replaced by bone.
Biocomposites' Managing Director Stephen Bratt said, "This independent clinical data in a maxillofacial indication, corroborates similar orthopaedic studies confirming that Biocomposites' ZPC technology, with a unique surface chemistry accelerates bone growth.
About the company:
Biocomposites is a privately held, leading developer, manufacturer and
distributor of synthetic, tissue regeneration products. Since 1997, the
company has developed a broad range of products that addresses the clinical
and economic needs of medical specialties in orthopae
|SOURCE Biocomposites Ltd|
Copyright©2009 PR Newswire.
All rights reserved